Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Altheos gets rights to Asahi Kasei's glaucoma compounds

Executive Summary

Altheos Inc. (ophthalmic therapeutics) has received exclusive global rights, except in Japan and Korea, to Asahi Kasei Pharma Corp.'s preclinical AK138 series of selective Rho kinase inhibitors for the topical treatment of glaucoma.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies